(453) A190, a new PPARα agonist loaded microemulsion for chemotherapy-induced peripheral neuropathy
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of anticancer agents. There are no approved preventive or treatment interventions for the CIPN.1 Fenofibrate, a Peroxisome Proliferator-Activated Receptor-Alpha (PPAR-α) agonist has demonstrated neuroprotective and analgesic properties; however, its clinical utility is hindered by low receptor affinity and suboptimal bioavailability.2 A190, a highly selective non-fibrate PPAR-α agonist, offers a promising alternative, but is limited by poor solubility, resulting in reduced oral bioavailability and therapeutic efficacy.3
Learning Objectives:
To understand the development and optimization of microemulsion systems.
To evaluate the therapeutic efficacy of oral A190 microemulsion for CIPN.
Surendra Poudel, Ph.D Student – Ph.D Student, Pharmaceutics, Virginia Commonwealth University; Sara Herz, Ph.D Student – Ph.D. Student, Pharmacology and Toxicology, Virginia Commonwealth University; Grant Berkbigler, Ph.D. Candidate – Ph.D. Candidate, Medicinal Chemistry, University of Minnesota; Adam Duerfeldt, Ph.D. – Associate Professor, Medicinal Chemistry, University of Minnesota; Imad Damaj, Ph.D. – Professor, Pharmacology and Toxicology, Virginia Commonwealth University; Qingguo Xu, D. Phil. – Associate Professor, Pharmaceutics, Virginia Commonwealth University
